The following is a summary of “Relevance of patient-centered actigraphy measures in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a qualitative interview study,” ...

may lead to pulmonary hypertension, a lethal complication of chronic pulmonary thromboembolism. There are few viable treatment options for pulmonary hypertension, but pulmonary ...

Treprostinil is under clinical development by United Therapeutics and currently in Phase III for Idiopathic Pulmonary Fibrosis.

The top articles about pulmonary arterial hypertension (PAH) in 2024 included FDA approvals, the effect of salt substitutes ...

Mosliciguat is under clinical development by Bayer and currently in Phase I for Kidney Disease (Nephropathy). According to GlobalData, Phase I drugs for Kidney Disease (Nephropathy) have a 71% phase ...

In the era of DOACs, risk for CTEPH following pulmonary embolism is affected by multiple factors, including gender and heart load.

Chronic High Blood Pressure During Pregnancy ... This difference becomes clear in pulmonary hypertension, in which only the lungs' blood vessels stiffen progressively, leading ...

Chronic heart failure (CHF ... now accounts for 7% of all deaths from cardiovascular disease. Hypertension (HTN) increases the risk of development of HF and it precedes it in 75% of cases.

Background Recommendations for venous thromboembolism (VTE) prophylaxis in patients with inflammatory bowel disease (IBD) can be refined by incorporating patient-specific risk factors. Objectives To ...

Rarely associated with obvious symptoms, hypertension can result in heart disease, vascular disease, stroke and/or chronic kidney disease ...